Aztreonam
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Aztreonam | LD 1000mg IV, then 500mg IV Q12H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 435 | 75 | 1.7-2.9 | 6-8 | 45-60 | 0.5-1.0 | 12.7-40 | 40 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Cunha B. Aztreonam. Urology 1993; 41(3), 249-58.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00355
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
- Sattler F, Schramm M, Swabb E. Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency. Reviews of infectious diseases 2012; 7( Suppl 4), S622-7.
- Nagasaka H, Inagaki O, Nakagawa K et al. Pharmacokinetics of Aztreonam on Hemodialysis. Japanese Journal of Antibiotics 1990; 43(2), 345-54.